FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

773956002: Lanadelumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3727208013 Lanadelumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3727209017 Lanadelumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
5535721000241111 lanadélumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Lanadelumab (substance) Is a Enzyme inhibitor false Inferred relationship Some
Lanadelumab (substance) Is a Kallikrein inhibitor true Inferred relationship Some
Lanadelumab (substance) This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context. Kallikrein inhibitor (disposition) true Inferred relationship Some
Lanadelumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Lanadelumab (substance) Is a Enzyme inhibitor protein true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Lanadelumab-containing product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Lanadelumab (substance) Inferred relationship Some 1
Lanadelumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Lanadelumab (substance) Inferred relationship Some 1
Product containing only lanadelumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Lanadelumab (substance) Inferred relationship Some 1
Lanadelumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Lanadelumab (substance) Inferred relationship Some 1
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Lanadelumab (substance) Inferred relationship Some 1
Product containing precisely lanadelumab 150 milligram/1 milliliter conventional release solution for injection (clinical drug) This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Lanadelumab (substance) Inferred relationship Some 1

This concept is not in any reference sets

Back to Start